CCL

Összesen 21 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM033721
Első szerző:András Csilla (onkológus szakorvos)
Cím:Docetaxel (Taxotere) az emlőrák neoadjuváns kezelésében / András Csilla, Szántó János
Dátum:2002
Tárgyszavak:Orvostudományok Klinikai orvostudományok magyar nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Pathology and oncology research. - 8 : Suppl. 2 (2002), p. 11-14. -
További szerzők:Szántó János (1949-) (onkológus szakorvos)
Borító:

2.

001-es BibID:BIBFORM034192
Első szerző:Becher, R.
Cím:Epirubicin and ifosfamide in metastatic breast cancer / R. Becher, O. Kloke, J. Hayungs, G. Hartwich, H. Bartels, J. Szanto, E. Wolf, H. J. Illiger, S. Halabi, K. Rieche, K. G. Hering, S. Ohl, R. DeDycker, R. Huhn, A. R. Fischedick, H. Höfeler, H. J. Pielken, I. Hawig, H. Hirche, S. Seeber
Dátum:1996
Megjegyzések:In a randomized, phase II trial, we evaluated the effectiveness of continued chemotherapy with epirubicin/ ifosfamide versus unmaintained treatment interruption in advanced metastatic breast cancer. Three hundred fifty-seven patients were enrolled and 331 were evaluable for response. Complete response was achieved in 25 patients (8%) and partial response in 121 patients (37%). Pretreatment status correlated significantly with response (complete and partial response). While 54% of unpretreated patients responded, only 42% of the patients responded who had been pretreated with adjuvant chemotherapy and 33% who had been pretreated in the metastatic stage of disease; 69 patients (21%) had disease progression. Of 11 patients pretreated in both the adjuvant and metastatic setting, only two responded. Toxicity of treatment was mild, with leukopenia being the treatment-limiting factor. Thrombocyte levels were not altered significantly by treatment. Thus, there seems to be room for dose escalation using granulocyte colony-stimulating factor. There was no considerable cardiotoxicity, central nervous system toxicity, or cystitis observed. The low rate of cardiotoxicity appeared to be related to dose fractionation of epirubicin. After randomization of patients to treatment interruption versus continuation of chemotherapy, a longer relapse-free survival was observed for patients who continued chemotherapy (mean relapse-free survival, 2+ months); however, this did not translate into prolonged survival. The cumulative scores of toxicity and quality of life parameters showed increasing superiority for treatment interruption. Therefore, a strategy of treatment until maximum response and subsequent treatment interruption seems to be superior to treatment continuation.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
külföldön készült közlemény
Megjelenés:Seminars in Oncology. - 23 : 3 Suppl. 7 (1996), p. 28-33. -
További szerzők:Kloke, O. Hayungs, J. Hartwich, G. Bartels, H. Szántó János (1949-) (onkológus szakorvos) Wolf, E. Illiger, H. J. Halabi, S. Rieche, K. Hering, K. G. Ohl, S. DeDycker, R. Huhn, R. Fischedick, A. R. Höfeler, H. Pielken, H. J. Hawig, I. Hirche, H. Seeber, S.
Borító:

3.

001-es BibID:BIBFORM046704
Első szerző:Boér Katalin
Cím:Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC) / Katalin Boér, István Láng, Éva Juhos, Tamás Pintér, János Szántó
Dátum:2003
Megjegyzések:he adjuvant chemotherapy of breast cancer changed in the past two decades. Docetaxel containing regimens are highly active in metastatic breast cancer. A logical approach was their incorporation into trials of early breast cancer adjuvant therapy. The authors present the Hungarian interim analysis and experience with the BCIRG 001 randomized, multicentric, phase III clinical trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) and FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients. The results are presented compared to the international data. Three Hungarian centers - Szt. Margit Hospital, Budapest, National Institute of Oncology, Budapest, Petz Aladár Hospital, Győr - participated in the international trial. Between June 1997 and June 1999, 61 patients with node positive breast cancer were enrolled in the study after the surgery. Thirty-four patients were randomized to TAC (75/50/500 mg/m2 6xq3wk) and 27 patients were randomized to FAC (500/50/500 mg/m2 6x q3wk) chemotherapy, with prospective stratification by node (1-3, 4+). Patients with hormone receptor positive tumors received tamoxifen for 5 years after the chemotherapy. Radiotherapy was performed after the 6th cycle of chemotherapy. 33 months of follow up was performed. In both arms the hematological toxicity was more frequent. The TAC group showed a higher incidence of neutropenia (76%) compared to the FAC (22%), as well as a higher incidence of febrile neutropenia (26 % versus none), without grade 3-4 infection and there was no cases of septic death. More grade 3-4 nausea and vomiting was observed in the FAC group. At three years follow up, results indicated improvement in disease-free survival (88% vs. 76%) in favour of TAC, and similar tendency was observed in the case of overall survival (97% vs. 88%). Based on the international data analysis TAC was superior to FAC chemotherapy, the results show statistically significant differences between the two arms. This benefit with TAC was seen regardless of hormone receptor status. Additional follow up data will evaluate the role of TAC in the adjuvant setting of early breast cancer treatment.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
early breast cancer
adjuvant chemotherapy
comparative study
docetaxel
Megjelenés:Pathology and Oncology Research. - 9 : 3 (2003), p. 166-169. -
További szerzők:Láng István Juhos Éva (onkológus) Pintér Tamás Szántó János (1949-) (onkológus szakorvos)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM034225
035-os BibID:WOS:A1988Q962000001 PMID:3054671
Első szerző:Eckhardt Sándor
Cím:Activity of epirubicin and dibromodulcitol in advanced breast cancer : results of the South-East European Oncology Group Study / Eckhardt S., Juhos É., Hindy I., Jelic S., Koza I., László G., Mechl Z., Nagykálnay T., Pawlicki M., Schoket Z., Siedlecki P., Svancarova L., Szántó J., Vuletic L., Zborzil J.
Dátum:1988
ISSN:0030-2414
Megjegyzések:The therapeutic efficacy of the combination of epirubicin + dibromodulcitol was evaluated in 108 previously treated or untreated patients with advanced breast cancer. The overall response rate was 39.8%, complete remission 3.7% (mean duration 6.3 months) and partial remission 36.1% (mean duration 3.5 months). The response was rated in function of age, menopausal status, performance status and previous therapy. Toxicity (in case of 115 patients) was evaluated according to the WHO recommendation. The similar therapeutic effectiveness and less toxicity of the above drug combination compared to ADM + DBD regimen are demonstrated.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
külföldön készült közlemény
Megjelenés:Oncology. - 45 : 6 (1988), p. 409-412. -
További szerzők:Juhos Éva (onkológus) Hindy Iván Jelic, S. Koza I. László G. Mechl, Z. Nagykálnay T. Pawlicki, Marek Schoket, Z. Siedlecki, P. Svancarová, L. Vuletic, L. Zborzil, J. Szántó János (1949-) (onkológus szakorvos)
Borító:

5.

001-es BibID:BIBFORM028323
Első szerző:Eckhardt Sándor
Cím:Activity of Epirubicin in Combination Chemotherapy of Advanced Ovarian Cancer / S. Eckhardt, J. Szántó, O. Cerar, V. Chylak, Z. Hernádi, I. Hindy, S. József, É. Juhos, K. Kolaric, J. Kopecny, I. Koza, Z. Mechl, K. Miksics, L. Németh, M. Pawlicki, S. Plesnicar, E. Ploch, Z. Schoket, Z. Stepanek, L. Svancarová, Z. Vizhányó, B. Zuchovska
Dátum:1987
ISSN:0030-2414
Megjegyzések:The therapeutic efficacy of the combination of cyclophosphamide + epirubicin + cisplatin was evaluated in 107 previously treated or untreated patients with advanced ovarian cancer. The overall response rate was 58.8%, complete remission 36.4% (mean duration-7.62 months) and partial remission 22.4% (mean duration-6.74 months). The response was rated in function of age, menopausal status, performance status and previous therapy. Toxicity (in case of 109 patients) was evaluated according to the WHO recommendation. The similar therapeutic effectiveness and less toxicity of the above drug combination compared to CAP regimen is demonstrated.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
petefészekrák
Megjelenés:Oncology. - 44 : 2 (1987), p. 69-72. -
További szerzők:Szántó János (1949-) (onkológus szakorvos) Cerar, O. Chylak, V. Hernádi Zoltán (1948-) (szülész-nőgyógyász, klinikai onkológus) Hindy Iván József Sándor Juhos Éva (onkológus) Kolaric K. Kopecny, J. Koza I. Mechl, Z. Miksics K. Németh L. Pawlicki, Marek Plesnicar, S. Ploch, E. Schoket, Z. Stepanek, Z. Svancarová, L. Vizhányó, Z. Zuchovska, B.
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM034248
Első szerző:Hindy Iván
Cím:Forms and results of mitolactol therapy / Hindy I., Szántó J., Bodrogi I., Farkas E., Eckhardt S.
Dátum:1980
ISSN:0030-2414
Megjegyzések:The authors give a summarizing report about mitolactol treatments performed in Hungary. As a single-agent therapy the drug was administered in two forms: (1) every-day therapy, 5 mg/kg/day, (2) push therapy, 10 mg/kg every 5th day or 15 mg/kg every 7th day, in a total dose of 100 mg/kg in both administration forms. Out of the solid tumours the squamous cell cancers proved to be the most responsive to mitolactol therapy: first of all in tumours of the head and neck and of the lung. The study also reports the preliminary results of polychemotherapeutical protocols containing mitolactol now in progress: (1) bleomycin + mitolactol (Bristol protocol), (2) carminomycin + mitolactol and (3) adriamycin + mitolactol.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Oncology. - 37 : Suppl.1. (1980), p. 115-117. -
További szerzők:Szántó János (1949-) (onkológus szakorvos) Bodrogi I. Farkas E. Eckhardt Sándor
Borító:

7.

001-es BibID:BIBFORM048802
035-os BibID:PMID:24163303
Első szerző:Hunyadi János (bőrgyógyász, kozmetológus, allergológus)
Cím:Autologous Dendritic Cell Based Adoptive Immunotherapy of Patients with Colorectal Cancer : a phase I-II study / János Hunyadi, Csilla András, Imre Szabó, János Szántó, Kornélia Szluha, Sándor Sipka, Péter Kovács, Attila Kiss, Gyula Szegedi, István Altorjay, Péter Sápy, Péter Antal-Szalmás, László Tóth, György Fazekas, Éva Rajnavölgyi
Dátum:2014
ISSN:1219-4956 1532-2807
Megjegyzések:Dendritic cell-based active immunotherapies of cancer patients are aimed to provoke the proliferation and differentiation of tumor-specific CD4+ and CD8+ T-lymphocytes towards protective effector cells. Isolation and in vitro differentiation of circulating blood monocytes has been established a reasonable platform for adoptively transferred DC-based immunotherapies. In the present study the safety and tolerability of vaccination by autologous tumor cell lysates (oncolysate)- or carcinoembriogenic antigen (CEA)-loaded DCs in patients with colorectal cancer was investigated in a phase I-II trial. The study included 12 patients with histologically confirmed colorectal cancer (Dukes B2-C stages). Six of the patients received oncolysate-pulsed, whereas the other six received recombinant CEA-loaded autologous DCs. The potential of the tumor antigen-loaded DCs to provoke the patient's immune system was studied both in vivo and in vitro. The clinical outcome of the therapy evaluated after 7 years revealed that none of the six patients treated with oncolysate-loaded DCs showed relapse of colorectal cancer, whereas three out of the six patients treated with CEA-loaded DCs died because of tumor relapse. Immunization with both the oncolysate- and the CEA-loaded autologous DCs induced measurable immune responses, which could be detected in vivo by cutaneous reactions and in vitro by lymphocyte proliferation assay. Our results show that vaccination by autologous DCs loaded with autologous oncolysates containing various tumor antigens represents a well tolerated therapeutic modality in patients with colorectal cancer without any detectable adverse effects. Demonstration of the efficacy of such therapy needs further studies with increased number of patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Pathology & Oncology Research. - 20 : 2 (2014), p. 357-365. -
További szerzők:András Csilla (1961-) (onkológus szakorvos) Szabó Imre Szántó János (1949-) (onkológus szakorvos) Szluha Kornélia (1955-) (radioterapeuta, radiológus, szülész-nőgyógyász, onkológus) Sipka Sándor (1945-) (laboratóriumi szakorvos) Kovács Péter (1947-) (belgyógyász, kardiológus, klinikai farmakológus) Kiss Attila (1942-) (belgyógyász, haematológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Sápy Péter (1942-) (sebész) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Tóth László (1971-) (patológus) Fazekas György Rajnavölgyi Éva (1950-) (immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM046701
035-os BibID:WOS:000181678300004 PMID:12637459
Első szerző:Nabholtz, Jean-Marc
Cím:Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial / Jean-Marc Nabholtz, Carla Falkson, Daniel Campos, Janos Szanto, Miguel Martin, Stephen Chan, Tadeuz Pienkowski, Jerzy Zaluski, Tamas Pinter, Maciej Krzakowski, Daniel Vorobiof, Robert Leonard, Ian Kennedy, Nacer Azli, Michael Murawsky, Alessandro Riva, Pierre Pouillart, TAX 306 Study Group
Dátum:2003
ISSN:0732-183X 1527-7755
Megjegyzések:This randomized, multicenter, phase III study compared doxorubicin and docetaxel (AT) with doxorubicin and cyclophosphamide (AC) as first-line chemotherapy (CT) in metastatic breast cancer (MBC). PATIENTS AND METHODS: Patients (n = 429) were randomly assigned to receive doxorubicin 50 mg/m(2) plus docetaxel 75 mg/m(2) (n = 214) or doxorubicin 60 mg/m(2) plus cyclophosphamide 600 mg/m(2) (n = 215) on day 1, every 3 weeks for up to eight cycles. RESULTS: Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048). The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009). The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%). Overall survival (OS) was comparable in both arms. Grade 3/4 neutropenia was frequent in both groups, although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01). Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%). CONCLUSION: AT significantly improves TTP and ORR compared with AC in patients with MBC, but there is no difference in OS. AT represents a valid option for the treatment of MBCújratöltve - BIBFORM034164
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal of Clinical Oncology. - 21 : 6 (2003), p. 968-975. -
További szerzők:Falkson, Carla Campos, Daniel Szántó János (1949-) (onkológus szakorvos) Martin, Miguel Chan, Stephen Pienkowski, Tadeuz Zaluski, Jerzy Pintér Tamás Krzakowski, Maciej Vorobiof, Daniel Leonard, Robert Kennedy, Ian Azli, Nacer Murawsky, Michael Riva, Alessandro Pouillart, Pierre TAX 306 Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM040078
035-os BibID:PMID:11173662
Első szerző:Orosz Zsolt (pathológus)
Cím:Pleomorphic liposarcoma of a young woman following radiotherapy for epithelioid sarcoma / Zsolt Orosz, Béla Rohonyi, Antal Luksander, János Szántó
Dátum:2000
Megjegyzések:A case of a metachronous epithelioid sarcoma and pleomorphic liposarcoma in a young woman is described. The first tumor was an epithelioid sarcoma (ES) with focal rhabdoid features localised in the left calf while the second lesion developed seven years later in the same region was diagnosed as pleomorphic liposarcoma resembling myxofibrosarcoma ( myxoid variant of malignant fibrous histiocytoma ) predominantly composed of moderately differentiated spindle cells. Multiple foci of uni- and plurivacuolated lipoblasts were seen. Following the resection of ES the patient received 57 Gy radiation to the region, therefore we regarded the second tumor as a radiation induced liposarcoma. A further interesting feature of this case is that the development of pleomorphic liposarcoma preceded by 6 months the solitary right parabronchial metastasis of ES and after 4 months of metastasectomy a third tumor developed at the site of the first lesion. This tumor showed dedifferentiation toward pleomorphic malignant fibrous histiocytoma. Our case represents a unique case of postirradiation liposarcoma developed on the base of ES.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény hazai lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Pathology and Oncology Research. - 6 : 4 (2000), p. 287-291. -
További szerzők:Rohonyi Béla Luksander Antal Szántó János (1949-) (onkológus szakorvos)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Szerző által megadott URL
DOI
Borító:

10.

001-es BibID:BIBFORM034239
035-os BibID:PMID:6843945 WOS:A1983QN84900012
Első szerző:Ottó Szabolcs
Cím:Monoclonal cryoimmunoglobulinemia of IgG4 subclass specificity / Ottó S., Szántó J., Börzsönyi M., Kocsis G.
Dátum:1983
ISSN:0030-2414
Megjegyzések:Authors demonstrated the prevalence of an unusual cryoimmunoglobulin with IgG4 subclass specificity in the blood of a patient with malignant lymphoproliferative disease. They provide the case history, results of immunochemical studies, and cytological and ultrastructural findings of the bone marrow.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Oncology. - 40 : 3 (1983), p. 205-209. -
További szerzők:Börzsönyi M. Kocsis G. Szántó János (1949-) (onkológus szakorvos)
Borító:

11.

001-es BibID:BIBFORM045967
035-os BibID:WOS:000225561100007
Első szerző:Pozzo, C.
Cím:Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma : results of a randomized phase II study / C. Pozzo, C. Barone, J. Szanto, E. Padi, C. Peschel, J. Bükki, V. Gorbunova, V. Valvere, J. Zaluski, M. Biakhov, E. Zuber, C. Jacques, R. Bugat
Dátum:2004
ISSN:0923-7534
Megjegyzések:Background: To identify the most effective of two combinations, irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) and irinotecan/cisplatin, in the treatment of advanced gastric cancer, for investigation in a phase III trial. Patients and methods: Patients were randomized to receive irinotecan [80 mg/m2 intravenously (i.v.)], FA (500 mg/m2 i.v.) and a 22-h infusion of 5-FU (2000 mg/m2 i.v.), weekly for 6 weeks with a 1-week rest, or irinotecan (200 mg/m2 i.v.) and cisplatin (60 mg/m2 i.v.), on day 1 for 3 weeks. Results: A total of 115 patients were eligible for analysis in the per-protocol population. The overall response rate in the irinotecan/5-FU/FA arm (n=59) was 42.4%, with a complete response rate of 5.1%. Corresponding figures for the irinotecan/cisplatin arm (n=56) were 32.1% and 1.8%, respectively. The median time to progression was 6.5 months (irinotecan/5-FU/FA) and 4.2 months (irinotecan/cisplatin) (P < 0.0001), with median survival times of 10.7 and 6.9 months, respectively (P=0.0018). The major toxicity was grade 3/4 neutropenia, which was more pronounced with irinotecan/cisplatin than with irinotecan/5-FU/FA (65.7% versus 27%). Diarrhea was the main grade 3/4 non-hematological toxicity with both irinotecan/5-FU/FA (27.0%) and irinotecan/cisplatin (18.1%). Conclusions: Both combinations were active, with acceptable safety profiles. Irinotecan/5-FU/FA was selected as the most effective combination for investigation in a phase III trial in advanced gastric cancer.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
külföldön készült közlemény
Megjelenés:Annals of Oncology. - 15 : 12 (2004), p. 1773-1781. -
További szerzők:Barone, C. Szántó János (1949-) (onkológus szakorvos) Pádi Éva Peschel, C. Bükki J. Gorbounova, Vera Valvere, V. Zaluski, J. Biakhov, M. Zuber, E. Jacques, C. Bugat, R.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM034942
Első szerző:Szántó János (onkológus szakorvos)
Cím:Letrozol : az emlőrák hormonális kezelésének újabb lehetősége / Szántó János
Dátum:2006
Tárgyszavak:Orvostudományok Klinikai orvostudományok magyar nyelvű folyóiratközlemény hazai lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Pathology and Oncology Research. - Különszám 1 (2006), p. 32-34. -
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.